296 related articles for article (PubMed ID: 17461854)
1. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
Hill A; Moyle G
HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
[TBL] [Abstract][Full Text] [Related]
2. Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
Cahn P; Villacian J; Lazzarin A; Katlama C; Grinsztejn B; Arasteh K; López P; Clumeck N; Gerstoft J; Stavrianeas N; Moreno S; Antunes F; Neubacher D; Mayers D
Clin Infect Dis; 2006 Nov; 43(10):1347-56. PubMed ID: 17051504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial.
Gathe J; Cooper DA; Farthing C; Jayaweera D; Norris D; Pierone G; Steinhart CR; Trottier B; Walmsley SL; Workman C; Mukwaya G; Kohlbrenner V; Dohnanyi C; McCallister S; Mayers D;
Clin Infect Dis; 2006 Nov; 43(10):1337-46. PubMed ID: 17051503
[TBL] [Abstract][Full Text] [Related]
4. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
[TBL] [Abstract][Full Text] [Related]
5. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
Hicks CB; Cahn P; Cooper DA; Walmsley SL; Katlama C; Clotet B; Lazzarin A; Johnson MA; Neubacher D; Mayers D; Valdez H;
Lancet; 2006 Aug; 368(9534):466-75. PubMed ID: 16890833
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
[TBL] [Abstract][Full Text] [Related]
7. Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
Hill A; Montaner J; Smith C
HIV Med; 2007 May; 8(4):234-40. PubMed ID: 17461851
[TBL] [Abstract][Full Text] [Related]
8. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
Haubrich R; Berger D; Chiliade P; Colson A; Conant M; Gallant J; Wilkin T; Nadler J; Pierone G; Saag M; van Baelen B; Lefebvre E;
AIDS; 2007 Mar; 21(6):F11-8. PubMed ID: 17413685
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of tipranavir boosted with ritonavir in HIV-1-infected patients failing multiple protease inhibitor regimens: 80-week data from a phase 2 study.
Markowitz M; Slater LN; Schwartz R; Kazanjian PH; Hathaway B; Wheeler D; Goldman M; Neubacher D; Mayers D; Valdez H; McCallister S
J Acquir Immune Defic Syndr; 2007 Aug; 45(4):401-10. PubMed ID: 17554217
[TBL] [Abstract][Full Text] [Related]
10. Hill A, Moyle G. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials. HIV Med 2007; 8: 259-264. Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
Llibre JM; Pérez-Alvarez N
HIV Med; 2007 Nov; 8(8):568-70; author reply 571-2. PubMed ID: 17944691
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of tipranavir in treatment-experienced HIV patients in the United States.
Simpson KN; Roberts G; Hicks CB; Finnern HW
HIV Clin Trials; 2008; 9(4):225-37. PubMed ID: 18753117
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
[TBL] [Abstract][Full Text] [Related]
13. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
14. Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
Youle M; Staszweski S; Clotet B; Arribas JR; Blaxhult A; Carosi G; Dejesus E; Di Perri G; Estrada V; Fisher M; Kovacs C; Kulasegaram R; Lazzarin A; Marriott D; Muñoz L; Reynes J; Shalit P; Slim J; Tsoukas C; Vaccaro A; Vera J
HIV Clin Trials; 2006; 7(2):86-96. PubMed ID: 16798623
[TBL] [Abstract][Full Text] [Related]
15. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
[TBL] [Abstract][Full Text] [Related]
17. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
18. Virologic response to tipranavir-ritonavir or darunavir-ritonavir based regimens in antiretroviral therapy experienced HIV-1 patients: a meta-analysis and meta-regression of randomized controlled clinical trials.
Berhan A; Berhan Y
PLoS One; 2013; 8(4):e60814. PubMed ID: 23593314
[TBL] [Abstract][Full Text] [Related]
19. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
[TBL] [Abstract][Full Text] [Related]
20. Tipranavir: PNU 140690, tipranivir.
Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
